This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Sesen Bio Dirección
Dirección controles de criterios 3/4
Información clave
Thomas Cannell
Chief Executive Officer (CEO)
US$4.9m
Compensación total
| Porcentaje del salario del CEO | 11.3% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 0.05% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 3.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | US$48m |
| Mar 31 2022 | n/a | n/a | US$54m |
| Dec 31 2021 | US$5m | US$558k | -US$336k |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$118m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$2m | US$533k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$60m |
| Dec 31 2019 | US$1m | US$520k | -US$107m |
| Sep 30 2019 | n/a | n/a | -US$81m |
| Jun 30 2019 | n/a | n/a | -US$82m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$2m | US$198k | -US$34m |
Compensación vs. Mercado: Thomas's total compensation ($USD4.92M) is about average for companies of similar size in the US market ($USD6.44M).
Compensación vs. Ingresos: Thomas's compensation has increased whilst the company is unprofitable.
CEO
Thomas Cannell (60 yo)
4.6yrs
Permanencia
US$4,921,698
Compensación
Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.6yrs | US$4.92m | 0.048% $ 1.2m | |
| CFO & Treasurer | 3.6yrs | US$1.87m | 0.036% $ 926.9k | |
| Chief Technology Officer | 6.1yrs | US$1.27m | 0.025% $ 645.2k | |
| Co-Founder | no data | sin datos | sin datos | |
| Corporate Controller & Principal Accounting Officer | 1.9yrs | sin datos | 0.050% $ 1.3m | |
| Vice President of Corporate Strategy & Investor Relations | no data | sin datos | sin datos | |
| General Counsel | 3.6yrs | US$1.15m | 0.022% $ 566.6k | |
| Vice President of Market Access | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 5.8yrs | sin datos | sin datos | |
| Chief Medical Officer | 4.3yrs | US$709.28k | sin datos | |
| Senior Director of Finance | 1.9yrs | sin datos | sin datos | |
| Chief Development Officer | 1.2yrs | sin datos | sin datos |
3.6yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: SESN's management team is considered experienced (3.6 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.6yrs | US$4.92m | 0.048% $ 1.2m | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman of the Board | 8.2yrs | US$251.28k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$469.77k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$215.91k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$219.01k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos |
3.1yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: SESN's board of directors are considered experienced (3.1 years average tenure).